The study, led by a team investigating the links between SARS-CoV-2 infection and hematologic abnormalities, was built around a central and stubborn question: COVID-19 is frequently accompanied by changes in blood counts, inflammatory disturbances, and signs of altered hematopoiesis, yet it has remained unclear whether the earliest hematopoietic compartments and the stromal cells that support them are directly touched by the virus or merely respond to it from a distance. To address this, the researchers designed in vitro exposure systems that allowed them to compare how adult mesenchymal stromal cells from two anatomical sources, and umbilical cord blood CD34-positive hematopoietic stem and progenitor cells, responded to wild-type SARS-CoV-2, the Delta variant, and the Omicron variant.

Mesenchymal stromal cells are a natural place to look for such interactions. They form part of the microenvironment — the niche — in which hematopoietic stem cells reside, divide, and commit to lineage fates. The team examined both adipose-derived mesenchymal stromal cells, obtained from fat tissue, and bone marrow-derived mesenchymal stromal cells. When these cultures were exposed to the three viral variants, the researchers looked for the viral nucleocapsid protein, a reliable marker of viral presence inside cells. What they found was a striking pattern of source- and variant-dependence: the proportion of cells showing nucleocapsid positivity varied depending both on where the stromal cells came from and on which viral variant was used, and it was highest with Omicron in the adipose-derived cells. Notably, however, infectious virus in the culture supernatants was undetectable, indicating that the stromal cells carried viral components without supporting a productive, replicative infection.

Why would Omicron preferentially leave its signature in adipose-derived stromal cells? A candidate emerged from a comparison of surface receptor expression. The adipose-derived cells expressed substantially higher levels of neuropilin-1, a host factor that has been implicated in SARS-CoV-2 entry, than their bone marrow-derived counterparts. Neuropilin-1 is known to bind the CendR motif, a polybasic sequence at the S1–S2 boundary of the viral spike protein, and earlier work had suggested it could act as an alternative or auxiliary entry route, particularly relevant to variants carrying characteristic polybasic cleavage-site features. To test whether neuropilin-1 mattered functionally, the researchers knocked the gene down in adipose-derived stromal cells. The result was telling: reducing neuropilin-1 levels diminished the Omicron-associated nucleocapsid signal, implicating an NRP1-linked entry process in the variant’s engagement of these cells. This connects the observed pattern of susceptibility to a defined molecular mechanism rather than leaving it as a mere correlation.

Beyond viral entry, the study examined how the stromal cells responded functionally to viral exposure. A particularly interesting finding involved indoleamine-2,3-dioxygenase 1, or IDO1, an immunoregulatory enzyme that catabolizes tryptophan along the kynurenine pathway and is known to modulate immune responses and contribute to immune escape and tolerance. SARS-CoV-2 exposure induced IDO1 in the stromal cells, with the most prominent induction occurring in the adipose-derived population. Because IDO1 activity can suppress T-cell responses and alter the local immune environment, its induction in niche-supporting cells suggests a mechanism by which viral encounter could subtly reconfigure the immunological tone of the stromal compartment, even in the absence of productive infection.

The most provocative part of the study concerns the hematopoietic side of the niche relationship. The researchers exposed umbilical cord blood CD34-positive hematopoietic stem and progenitor cells — the population containing the most primitive blood-forming cells — to the viral variants. With Omicron, several coordinated changes emerged. Nucleocapsid positivity appeared within the CD34-positive population and, critically, was enriched in the long-term hematopoietic stem cell fraction, the most primitive and self-renewing compartment. At the same time, the frequencies of primitive fractions were reduced, suggesting a shift in the composition of the population away from its most immature elements. Heat-inactivated virus did not produce these effects, indicating that active viral material, not merely the physical presence of viral particles, drove the response.

Functionally, the Omicron-exposed progenitors did not simply decline. Instead, they reorganized their output. Colony formation — the standard assay in which progenitors are plated in semisolid medium and give rise to clusters of mature blood cells — increased after Omicron exposure, and the cultures showed an accumulation of early erythroid progenitors. This combination of reduced primitive fractions, heightened colony-forming activity, and erythroid-skewed output is characteristic of stress-responsive hematopoiesis, the emergency mode of blood production in which the stem cell compartment is pushed toward differentiation to meet acute demands. The implication is that Omicron exposure can promote the remodeling of early blood formation toward a stress-response program, at least in this in vitro setting.

To understand the molecular underpinnings of these changes, the team performed transcriptional profiling using the NanoString platform. The analysis revealed activation of host-response programs and, importantly, alterations in cell-cycle and differentiation programs within the exposed cells. Such transcriptional shifts provide a coherent framework for the phenotypic observations: changes in cell-cycle gene expression could explain shifts in the balance between quiescence and proliferation, while altered differentiation programs align with the observed erythroid bias and increased colony output. Together, the profiling data and the functional assays support a model in which viral engagement of primitive hematopoietic cells triggers a coordinated transcriptional and functional remodeling, rather than a nonspecific toxic effect.

The authors are careful about what their data do and do not show. The exposure systems were in vitro, and infectious virus was not recovered from the stromal cultures, so the findings do not establish that mesenchymal stromal cells or hematopoietic stem cells support viral replication in the body. The cord blood experiments likewise demonstrate viral protein presence and transcriptional and functional changes rather than a productive infection. Nevertheless, the combination of results — variant-dependent nucleocapsid detection, a receptor-linked entry mechanism, immunomodulatory enzyme induction, and lineage-remodeling in primitive progenitors — indicates that Omicron can physically engage both stromal and early hematopoietic compartments in a biologically meaningful way. These observations offer a plausible mechanistic bridge to the hematologic abnormalities reported in COVID-19 patients and identify neuropilin-1 and the stress-hematopoiesis axis as candidate targets for future investigation into the long-term consequences of SARS-CoV-2 exposure on the blood system.

Subject of Research: Omicron SARS-CoV-2 interaction with mesenchymal stromal cells and cord blood CD34-positive hematopoietic stem and progenitor cells

Article Title: Omicron SARS-CoV-2 shows NRP1-linked susceptibility in adipose-derived MSCs and alters primitive cord blood CD34⁺ HSPCs

Article References: Bhukhai, K., Tanhuad, N., Srimorkun, P., Manopwisedjaroen, S., Panvongsa, W., Vacharathit, V., Kanjanasirirat, P., Thongsa-ad, U., Kongsomros, S., Sutjarit, N., Srisaowakarn, C., Tawonsawatruk, T., Wongtrakoongate, P., Boonmuen, N., Borwornpinyo, S., Anurathapan, U., Chairoungdua, A., Asavapanumas, N., Hongeng, S., & Thitithanyanont, A. (2026). Omicron SARS-CoV-2 shows NRP1-linked susceptibility in adipose-derived MSCs and alters primitive cord blood CD34⁺ HSPCs. PLOS One, 21(10), e0360439. https://doi.org/10.1371/journal.pone.0360439

Image Credits: AI Generated

DOI: 10.1371/journal.pone.0360439

Keywords: SARS-CoV-2, Omicron, NRP1, mesenchymal stromal cells, CD34-positive HSPCs, hematopoiesis, cord blood, IDO1, nucleocapsid protein, erythroid progenitors, Delta variant, viral entry

The finding matters because tryptophan is not just any nutrient in the tug-of-war between host and pathogen. When the immune system detects M. tuberculosis, interferon-gamma-activated macrophages switch on an enzyme called indoleamine 2,3-dioxygenase 1, or IDO1, whose job is to degrade tryptophan inside the cell. This is a deliberate host defense: starve the invader of an amino acid it cannot easily live without. Although M. tuberculosis is a tryptophan prototroph, meaning it carries the genes to synthesize the amino acid from scratch, it normally prefers to scavenge tryptophan from its host because building it de novo is energetically expensive. The bacterium can sense when tryptophan becomes scarce and responds by inducing its own biosynthetic pathway, but until now the mechanism linking that sensing to the compensatory response remained obscure.

The new work points to VapC37 as the missing link. VapC37 belongs to a family of toxin–antitoxin systems, genetic modules in which a toxin protein is normally kept in check by a labile antitoxin; under stress, the antitoxin degrades and the toxin acts. When the researchers expressed VapC37 in the bacterium, growth arrested. Biochemical characterization showed that the toxin is a highly selective ribonuclease, or tRNase, that exclusively depletes tRNA carrying tryptophan. In other words, out of the entire complement of transfer RNAs the bacterium needs to translate its genes, VapC37 cleaves only the one dedicated to tryptophan. That precision is what makes the system so elegant: rather than causing indiscriminate damage, the toxin produces a very specific molecular signal.

The consequence of that signal is a state of perceived tryptophan starvation. With tRNA-Trp gone, the bacterium behaves as though the amino acid were unavailable, and it upregulates the production of enzymes in the tryptophan biosynthetic pathway. The toxin therefore appears to couple intracellular tryptophan availability—a well-established regulator of M. tuberculosis growth—to a codon-dependent adaptive response that raises the intracellular concentration of the amino acid. In effect, the bacterium uses its own toxin as an internal alarm, converting a host-imposed nutrient limitation into a genetic program that restores the nutrient supply.

But the toxin does far more than sound the alarm. The study shows that VapC37 broadly reprograms both the transcriptome, the full set of messenger RNAs, and the translatome, the set of mRNAs actually being made into proteins, toward molecules with low or no tryptophan codons. This makes intuitive sense: if the adaptor for tryptophan codons has been destroyed, genes rich in those codons will stall on the ribosome, while genes that avoid them can still be translated efficiently. The bacterium effectively reorients its protein production away from tryptophan-heavy messages, a genome-wide shift in metabolic priorities that mirrors the codon composition of the genes themselves.

Then comes the study’s most striking exception. Key enzymes in the biosynthetic pathway for phthiocerol dimycocerosate, or PDIM, a lipid critical to the bacterium’s virulence, were robustly synthesized despite being large proteins studded with tryptophan codons. Under the logic of codon depletion, these messages should have been among the hardest hit. Instead, the bacterium preserved their translation, and PDIM lipid production more than doubled upon VapC37 expression. This selective enrichment suggests that M. tuberculosis actively protects the machinery for making PDIM even under conditions of tRNA-Trp limitation, prioritizing a virulence factor over the general economy of codon scarcity.

PDIM is no incidental molecule. The waxy lipid is a well-known contributor to the bacterium’s early immune escape and virulence, helping it maintain its protective cell envelope and resist host defenses during the crucial early phase of infection. The finding that the bacterium selectively preserves PDIM production while everything else shifts toward tryptophan conservation implies a carefully choreographed reallocation of resources: the pathogen simultaneously defends its nutrient supply and its armor. That dual strategy could help explain how M. tuberculosis manages to keep replicating in an environment where the host is actively trying to starve and kill it.

The researchers also looked for clues about when VapC37 might actually be deployed during infection. They found that transcripts of the vapBC37 toxin–antitoxin module, along with PDIM biosynthetic transcripts, are upregulated when M. tuberculosis cells are subjected to nitrosative stress, a form of reactive nitrogen attack that macrophages use against engulfed pathogens, and upon infection of THP-1 macrophage-like cells. This pattern implicates early macrophage-associated stresses as potential activators of the toxin. If VapC37 switches on when the bacterium first encounters the hostile interior of an activated macrophage, it could serve as an early-response mechanism, reallocating metabolic priorities toward tryptophan biosynthesis while selectively maintaining PDIM production at the very moment the pathogen needs it most to evade immune clearance.

The study adds to a growing appreciation of toxin–antitoxin systems as regulatory tools rather than mere genomic parasites. In M. tuberculosis, which carries an unusually large number of these modules, individual toxins appear to have been recruited for specific stress responses. VapC37’s role as a tRNA-targeting switch that converts host-imposed tryptophan depletion into a compensatory biosynthetic program offers a concrete mechanism for how the pathogen links nutrient sensing to gene regulation. It also highlights the codon as a regulatory unit: because the toxin’s effect is codon-dependent, the amino acid composition of each gene determines how strongly it is affected, giving the bacterium a built-in hierarchy of what gets made and what gets shelved during stress.

For the field of tuberculosis research, the work opens several avenues. Understanding precisely how VapC37 is activated inside host cells, how the bacterium achieves selective translation of PDIM enzymes despite tryptophan codon depletion, and whether other toxin–antitoxin systems perform analogous roles under different stresses could reveal new vulnerabilities in a pathogen that has proved notoriously difficult to eradicate. With drug-resistant strains of M. tuberculosis continuing to spread, mechanisms that operate at the interface of host immunity and bacterial metabolism—such as the tryptophan tug-of-war mediated by IDO1 and countered by VapC37—are increasingly attractive targets for therapeutic intervention. The new study, published in PLOS Pathogens, demonstrates that even a single tRNA molecule can be the fulcrum on which a global pathogen balances survival, adaptation, and virulence.

Subject of Research: Toxin-mediated tRNA depletion and codon-dependent stress adaptation in Mycobacterium tuberculosis

Article Title: Toxin-mediated tRNA Trp depletion drives Trp-codon-dependent reprogramming in Mycobacterium tuberculosis while selectively enriching the PDIM biosynthetic machinery

Article References: Sain, S., Chauhan, U., Barth Jr, V. C., Troian, E. A., Abbadi, B. L., Malakar, B., Husson, R. N., & Woychik, N. A. (2026). Toxin-mediated tRNATrp depletion drives Trp-codon-dependent reprogramming in Mycobacterium tuberculosis while selectively enriching the PDIM biosynthetic machinery. PLOS Pathogens, 22(10), e1014679. https://doi.org/10.1371/journal.ppat.1014679

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014679

Keywords: Mycobacterium tuberculosis, VapC37, toxin-antitoxin system, tRNA-Trp, tryptophan biosynthesis, PDIM, IDO1, macrophage, nitrosative stress, translatome, virulence, PLOS Pathogens

The biological rationale behind the trial was compelling. Many tumors defend themselves not just by hiding from immune cells but by actively poisoning the local environment in which those cells operate. One of the most notorious mechanisms involves indoleamine 2,3-dioxygenase-1, or IDO1, an enzyme that catabolizes the essential amino acid tryptophan into kynurenine. When IDO1 is highly active, tryptophan levels in the tumor microenvironment fall while kynurenine levels rise. This metabolic shift is doubly damaging: T cells deprived of tryptophan become dysfunctional and can even undergo stress responses, while kynurenine itself promotes immunosuppressive signaling. The ratio of kynurenine to tryptophan, often abbreviated Kyn/Trp, therefore serves as a convenient biochemical readout of IDO1 activity and of the metabolic hostility of a tumor’s surroundings.

To neutralize this mechanism, the investigators used epacadostat, known in earlier development as INCB024360, an oral small-molecule inhibitor of IDO1 supplied by Incyte Corporation. Patients received 300 milligrams twice daily starting on day zero. Three weeks later, beginning on day 21, they also received MELITAC 12.1, a multipeptide vaccine developed to stimulate T cells against multiple melanoma antigens simultaneously. The idea was a classic one-two punch: the vaccine would expand armies of T cells primed to recognize melanoma, while the IDO1 inhibitor would strip away the metabolic defenses that tumors use to disable those armies once they arrive. The trial enrolled eleven eligible patients with measurable regional or distant melanoma metastases.

A distinctive strength of the study was its insistence on looking inside the tumor, not just at the bloodstream. Patients underwent tumor biopsies at three time points: before treatment, on day 21, and on day 42. Some patients also underwent resection of all clinically evident disease by day 42, providing additional tissue for analysis. The prespecified primary immunologic endpoint was an increase in CD8-positive tumor-infiltrating lymphocytes, the cytotoxic T cells that can directly kill tumor cells, measured by immunohistochemistry. Circulating T cell responses were tracked using interferon-gamma ELIspot assays, while inhibition of IDO1 was assessed by measuring kynurenine and tryptophan levels in both serum and tumor tissue.

On the safety front, the combination performed respectably. Two of the eleven subjects, about 18 percent, experienced dose-limiting toxicities that were transient, and the regimen was otherwise well tolerated. This matters because combination immunotherapies often stack toxicities on top of one another, and a tolerable pairing preserves options for future development. The biochemical data were likewise encouraging. Epacadostat normalized serum kynurenine-to-tryptophan ratios in 91 percent of subjects, demonstrating that the drug was doing exactly what it was designed to do systemically. Perhaps more importantly, the drug also reduced Kyn/Trp ratios inside the tumors themselves, although pretreatment intratumoral ratios varied widely from patient to patient, hinting that IDO1-driven immunosuppression may be relevant in some tumors but not others.

Here, however, the trial’s central hypothesis ran aground. The prespecified primary endpoint, an increase in total CD8-positive T cell infiltration within tumors, was not met. Blocking IDO1, whether alone or in combination with the vaccine, did not meaningfully increase the number of cytotoxic T cells crowding into the tumor microenvironment. This finding lands as part of a broader reckoning with the IDO1 field. Enthusiasm for IDO1 inhibitors was once enormous, but large randomized trials of epacadostat in combination with checkpoint inhibitors in melanoma failed to improve clinical outcomes, and the present study adds mechanistic texture to that disappointment: the drug reliably lowers kynurenine, yet lowering kynurenine alone does not summon more killer T cells into tumors.

The vaccine component also produced puzzling results. In one subject, a day-42 tumor contained T cells reactive to peptides included in the vaccine, a tantalizing sign that vaccine-primed cells could reach tumor tissue. Unfortunately, no baseline tumor sample was available from that patient, making it impossible to determine whether those cells had been recruited or expanded as a result of treatment. More broadly, circulating T cell responses measured by ELIspot were lower than those seen in prior studies of the vaccine given alone, raising the possibility that the IDO1 inhibitor, or the sequencing of the two treatments, somehow blunted rather than enhanced vaccine-induced immunity. That counterintuitive observation alone justifies further mechanistic study.

Clinically, the trial was too small to draw firm conclusions about efficacy, but the signals were modest at best. Among five patients evaluable for clinical response, the best response was a partial remission in one subject, stable disease in three, and progressive disease in one. The partial response was transient. The authors conclude that these findings do not support routine combination of the MELITAC 12.1 vaccine with epacadostat, an honest negative result that spares future patients from an unpromising regimen and redirects resources toward more rational strategies.

Yet the study is far from a dead end. The observation that pretreatment intratumoral Kyn/Trp ratios varied widely suggests a biomarker-driven path forward: rather than giving IDO1 inhibitors to everyone, clinicians might identify the subset of patients whose tumors are genuinely dependent on IDO1-mediated metabolic suppression and treat only those individuals. The authors explicitly note that there may be value in targeted study of IDO1 inhibitors for tumors with the highest kynurenine-to-tryptophan levels. This kind of sequential tumor biopsy design, sampling the microenvironment before and during therapy, is exactly the sort of translational rigor that turns failed trials into roadmaps.

The trial also stands as a testament to collaborative infrastructure. It was funded by an NIH/NCI grant supporting the Cancer Immunotherapy Trials Network, with additional support from cancer center grants at the Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium and the University of Virginia Cancer Center, along with philanthropic support for vaccine peptide production. Specialized analyses of gene expression, IDO1 content, and tumor metabolites were performed with partners including NanoString Technologies and ImaBiotech. In an era when immunotherapy headlines often celebrate dramatic successes, this study is a reminder that negative results, when paired with deep biological measurement, are among the most instructive outputs of clinical science. Eleven patients, three biopsies each, and a meticulously measured metabolic axis have clarified where one immunotherapeutic combination does not work, and pointed toward where it still might.

Subject of Research: A phase II trial combining an IDO1 inhibitor with a multipeptide vaccine in advanced melanoma

Article Title: A phase II pilot trial of an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor (INCB024360) plus a multipeptide melanoma vaccine (MELITAC 12.1) in patients with advanced melanoma, with sequential evaluation of the tumor microenvironment

Article References: Slingluff, C. L., Ernstoff, M. S., Lawson, D., Delman, K. A., Hanks, B. A., Gastman, B., Mauldin, I. S., Olson, W. C., Ninmer, E. K., Gradecki, S. E., Smith, K. T., Gru, A., Ramchurren, N., Morishima, C., Fling, S. P., Kaiser, J. C., & Cheever, M. A. (2026). A phase II pilot trial of an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor (INCB024360) plus a multipeptide melanoma vaccine (MELITAC 12.1) in patients with advanced melanoma, with sequential evaluation of the tumor microenvironment. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04572-z

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04572-z

Keywords: melanoma, IDO1, epacadostat, cancer vaccine, immunotherapy, tumor microenvironment, kynurenine, tryptophan, CD8 T cells, clinical trial, Cancer Immunotherapy Trials Network, tumor-infiltrating lymphocytes

The study, led by Soledad Bouquez and Paola López Campos under the direction of corresponding author Maite Duhalde-Vega, examined mice fed a high-fat diet, a model that reliably reproduces the metabolic disturbances seen in human obesity. High-fat diets have long been implicated in metabolic disorders through mechanisms involving hyperuricemia, gut dysbiosis, and intestinal barrier dysfunction, but the precise chain of cause and effect has remained elusive. The Argentine team set out to determine whether pharmacological reduction of uric acid could interrupt that chain, and if so, by what molecular route.

The results were striking. Mice on the high-fat diet developed hyperuricemia, and their gut microbial communities shifted into a dysbiotic state characterized by an expansion of Proteobacteria, a phylum widely regarded as a microbial signature of epithelial dysfunction, along with altered ratios of Firmicutes to Bacteroidetes, a compositional change repeatedly linked to obesity and type 2 diabetes in human studies. At the same time, the animals’ intestines mounted an inflammatory program: levels of the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α rose, while the anti-inflammatory mediators IL-10 and IL-22 declined. The team also detected increased serum lipopolysaccharide, or LPS, indicating that bacterial products were leaking across a compromised intestinal wall into the circulation, fueling systemic inflammation marked by elevated IL-6 and C-reactive protein.

When the researchers added allopurinol to the high-fat diet, the picture changed dramatically. The drug, which inhibits xanthine oxidase and thereby blocks uric acid production, normalized serum uric acid levels and, with them, restored microbial balance. The dysbiotic expansion of Proteobacteria receded, the Firmicutes/Bacteroidetes ratio shifted back toward a healthier profile, and the inflammatory storm in the gut subsided. Pro-inflammatory cytokines fell, protective IL-10 and IL-22 recovered, serum LPS dropped, and markers of intestinal barrier dysfunction improved. Equally important, the systemic inflammatory signs, elevated circulating IL-6 and CRP, diminished, suggesting that repairing the gut wall had consequences well beyond the intestine itself.

The most mechanistically revealing part of the study concerned tryptophan metabolism, an increasingly central theme in gut immunology. Tryptophan, an essential amino acid obtained from the diet, can be metabolized along several competing routes. One route, driven by the enzyme indoleamine 2,3-dioxygenase 1, or IDO1, shunts tryptophan toward catabolites that are generally associated with inflammation and immune suppression. Another route, carried out by gut bacteria, produces indoles, small molecules that serve as ligands for the aryl hydrocarbon receptor, or AhR, a transcription factor expressed in immune and epithelial cells. When AhR is activated by these microbial indoles, it promotes the production of interleukin-22, a cytokine that strengthens epithelial barrier function, stimulates antimicrobial peptide release, and maintains mucosal homeostasis.

In the high-fat diet mice, this protective circuitry was broken. The animals showed increased IDO1 activity and diminished indole production, tilting tryptophan metabolism away from AhR-activating ligands and toward inflammatory catabolites. Allopurinol treatment reversed this shift: IDO1 activity decreased and indole production was restored, replenishing the supply of microbial metabolites capable of engaging AhR. The result was a reinvigorated AhR–IL-22 axis, which the authors identified as the key mediator of the drug’s gut-protective effects. Prior work, including landmark studies showing that tryptophan catabolites from the microbiota engage AhR and balance mucosal reactivity via interleukin-22, had established the plausibility of this pathway; the new study ties it directly to uric acid metabolism.

To prove that the AhR–IL-22 axis was not merely correlated with the improvements but actually required for them, the team employed CH-223191, a selective pharmacological antagonist of the aryl hydrocarbon receptor. When AhR signaling was blocked in allopurinol-treated mice, the drug’s anti-inflammatory and barrier-protective effects were reversed. Cytokine profiles deteriorated, barrier function declined, and the benefits of uric acid reduction evaporated. This loss-of-function experiment provides functional evidence, not just associative data, that the AhR/IL-22 axis mediates gut protection in this model, a level of mechanistic rigor that strengthens the study’s therapeutic implications considerably.

The findings arrive amid growing interest in the interplay between purine metabolism, the microbiome, and intestinal health. Previous research has shown that hyperuricemia is associated with immune disorders and intestinal barrier dysfunction, that gut bacterial metabolism contributes to host purine homeostasis, and that hyperuricemia can influence tryptophan metabolism by inhibiting the transport proteins MRP4 and BCRP, which handle uric acid and metabolite trafficking across cell membranes. Uric acid itself is no innocent molecule: it was identified nearly two decades ago as a danger signal that alerts the immune system to dying cells, and elevated levels have been linked to metabolic syndrome through the activity of xanthine oxidoreductase. The new study weaves these threads into a coherent narrative in which dietary fat raises uric acid, uric acid disrupts the microbiome and tryptophan handling, and the resulting loss of AhR ligands starves the gut of the IL-22 signal it needs to maintain its barrier.

For clinicians, the appeal of the proposed strategy lies in its practicality. Allopurinol is inexpensive, generically available, and already used by millions of patients with gout and hyperuricemia, with a well-characterized safety profile. If the mechanisms observed in mice translate to humans, targeting hyperuricemia could offer a repurposable intervention for metabolic and inflammatory gut diseases, conditions that currently have limited therapeutic options. The authors suggest that uric acid modulation deserves consideration as a promising therapeutic strategy for these disorders, though they and outside observers alike will caution that mouse models of diet-induced disease do not always recapitulate human pathophysiology, and that clinical trials would be needed before uric acid lowering could be recommended for gut inflammation specifically.

The study also adds to a rapidly expanding literature on how diet reshapes the gut microbiome and, through it, systemic health. High-fat diets have been shown to alter microbial and metabolite profiles during obesity, to increase intestinal permeability, and to drive gut dysbiosis and inflammation that contribute to obesity-associated liver disease. Microbiota-targeted interventions, including washed microbiota transplantation in gout patients, have already shown hints of benefit on serum uric acid and intestinal barrier function in early pilot studies. What distinguishes the new work is its demonstration of a complete, mechanistically validated pathway, from dietary fat to uric acid to microbial composition to tryptophan-derived metabolites to AhR activation to IL-22-dependent barrier protection, with pharmacological confirmation at each critical node. That level of pathway resolution is rare, and it transforms a loose association between gout drugs and gut health into a testable therapeutic hypothesis.

The research, supported by grants from Argentina’s National Agency of Science and Technology and the Universidad de Buenos Aires, was conducted under approved animal care protocols and published as an original article in the Journal of Molecular Medicine. As obesity rates continue to climb worldwide and inflammatory bowel diseases grow more prevalent, the idea that a fifty-year-old gout medication might protect the gut by feeding the microbiome’s chemical conversation with the immune system is the kind of unexpected, cross-disciplinary insight that could reshape how clinicians think about the drugs they already prescribe. The next step will be determining whether lowering uric acid in people delivers the same tryptophan-centered, AhR-mediated protection that it does in mice, a question that the authors’ elegant mechanistic framework now makes far easier to ask.

Subject of Research: How anti-hyperuricemia therapy with allopurinol alleviates diet-induced gut inflammation in mice via the AhR–IL-22 signaling axis

Article Title: Anti-hyperuricemia therapy alleviates diet-induced gut inflammation via AhR-IL-22-signalling

Article References: Bouquez, S., Campos, P. L., Ottobre, M., & Duhalde-Vega, M. (2026). Anti-hyperuricemia therapy alleviates diet-induced gut inflammation via AhR-IL-22-signalling. Journal of Molecular Medicine, 104(1), Article 105. https://doi.org/10.1007/s00109-026-02713-6

Image Credits: AI Generated

DOI: 10.1007/s00109-026-02713-6

Keywords: hyperuricemia, allopurinol, uric acid, gut microbiota, gut inflammation, intestinal barrier, AhR, IL-22, tryptophan metabolism, indole, IDO1, high-fat diet

The review, authored by Isabela Gontijo, Mariana Camurça and José Roberto Kfoury of the University of São Paulo, systematically dissects why IDO1-targeted drugs have underperformed in the clinic. The most famous failure was epacadostat, which, despite robustly lowering kynurenine when combined with pembrolizumab in a randomized phase 2 study in metastatic non-small-cell lung cancer, did not improve objective response rates over pembrolizumab alone. The authors argue that such disappointing results should not be read as evidence that the drug failed to engage its target. Instead, they propose, IDO1 operates within a distributed metabolic network in which substrate availability, alternative enzymes, non-enzymatic signaling, cell-specific metabolic programs, downstream receptors and even the gut microbiome can each sustain tryptophan-dependent immunoregulation after the primary enzyme is pharmacologically silenced.

To appreciate the scale of the problem, it helps to understand how IDO1 works. The enzyme is a cytosolic, heme-containing oxidoreductase expressed in dendritic cells, macrophages, stromal cells and cancer cells. Its transcription is induced when interferon-gamma binds its receptor, activating JAK1 and JAK2 kinases that phosphorylate STAT1. Phosphorylated STAT1 dimers, known as gamma-activated factor, translocate to the nucleus and bind gamma-activated sites in the IDO1 promoter, while a secondary wave of interferon regulatory factor 1 amplifies the signal through interferon-stimulated response elements. Once made, IDO1 is catalytically active only when its heme iron is in the reduced ferrous state, allowing it to cleave the indole ring of L-tryptophan and generate N-formyl-L-kynurenine, which arylformamidase rapidly converts to L-kynurenine. This step is the rate-limiting entry point of tryptophan into the kynurenine pathway, which ultimately feeds de novo NAD+ biosynthesis.

The downstream consequences of this reaction extend well beyond substrate consumption. Tryptophan depletion activates the GCN2 integrated stress response while dampening mTORC1 signaling, the nutrient-sensing hub that drives protein translation, cell-cycle progression and clonal expansion in activated T lymphocytes. Meanwhile, accumulated kynurenine acts as an endogenous ligand for the aryl hydrocarbon receptor, which sheds its cytoplasmic chaperone complex, enters the nucleus, pairs with ARNT and switches on a tolerogenic transcriptional program in antigen-presenting and myeloid cells. This favors regulatory T-cell differentiation and blunts effector immunity, although the review is careful to note that AHR biology is context dependent: in some settings, such as resident-memory CD8-positive T cells and natural killer cells, AHR activity actually enhances antitumor function. IDO1 also has a second, entirely non-enzymatic identity. In TGF-beta-conditioned dendritic cells, the enzyme is phosphorylated on immunoreceptor tyrosine-based inhibitory motifs by the Src-family kinase Fyn, recruiting the phosphatases SHP-1 and SHP-2 and triggering non-canonical NF-kappa-B signaling through p52/RelB complexes, a positive feedback loop that sustains long-term immune tolerance independently of catalysis.

Against this backdrop, the review catalogs a series of compensatory routes that survive IDO1 blockade. The first is enzymatic redundancy. Tryptophan 2,3-dioxygenase 2, or TDO2, is a hepatic, glucocorticoid-regulated heme enzyme that catalyzes exactly the same initial reaction as IDO1, oxidizing tryptophan to N-formyl-L-kynurenine. Because selective IDO1 inhibitors leave the substrate itself untouched, any cell expressing active TDO2 can simply absorb the surplus tryptophan and feed it back into the kynurenine pathway, preserving kynurenine-dependent AHR signaling without any restoration of IDO1 activity. Its paralog IDO2, encoded next to IDO1, has weak catalytic efficiency but may contribute through membrane-associated signaling functions of its own. This mechanistic logic underlies the development of dual IDO1/TDO2 inhibitors such as M4112 and SHR9146, which are designed to close both enzymatic entry points simultaneously.

A second form of compensation is metabolic rerouting. When IDO1-dependent consumption falls, more tryptophan remains available to competing enzymes, including tryptophan hydroxylase 1 and 2, which commit the amino acid to the serotonergic pathway instead. The resulting surge in 5-hydroxytryptophan and serotonin does not simply vanish into a metabolic dead end: serotonin is itself an extracellular signaling molecule, sensed by a family of G-protein-coupled receptors and the ion-channel receptor 5-HT3 on monocytes, macrophages, dendritic cells and lymphocytes, where it modulates cytokine production, migration and differentiation. Serotonin can be further converted to melatonin through AANAT and ASMT, adding another layer of immunomodulatory chemistry. Clinical evidence supports this rewiring: in ovarian cancer patients treated with an IDO1 inhibitor, tumor metabolic adaptation toward the serotonin pathway was documented and found to constrain antitumor immune responses.

A third route runs through IL4I1, a secreted FAD-dependent amino acid oxidase induced by interleukin-4 that oxidizes tryptophan to indole-3-pyruvic acid, releasing ammonia and hydrogen peroxide. Because this chemistry is fundamentally different from heme-dependent dioxygenation, IDO1 inhibitors have no direct effect on it. Yet the indole metabolites IL4I1 produces, including indole-3-aldehyde, are potent AHR ligands, meaning the pathway bypasses the kynurenine step entirely while converging on the same tolerogenic receptor. Recent studies have linked IL4I1/AHR signaling to macrophage polarization in allergic rhinitis and to anti-inflammatory programs in cytokine-primed muscle stem cells, underscoring how a single receptor can be fed by multiple, pharmacologically independent metabolic tributaries.

The review also elevates compensation from the single-cell to the tissue level. Tryptophan transporters such as LAT1 and SLC7A11 are distributed unevenly across cell types, so when IDO1-expressing cells stop consuming tryptophan, neighboring cells with high transporter activity act as alternative metabolic sinks, redirecting the shared substrate according to their own enzymatic repertoires. Single-cell RNA sequencing in inflammatory intestinal tissue has revealed sharply different tryptophan-metabolic profiles among macrophages, fibroblasts and epithelial cells, while work in macrophages shows that efferocytosis induces a coordinated program of tryptophan uptake, IDO1 expression and kynurenine production that aids tissue resolution. In this non-cell-autonomous model, substrate consumption, metabolite production and metabolite sensing can all occur in different compartments of the same tissue, which means that inhibiting one enzymatic source may merely reshuffle the cellular geography of tryptophan metabolism rather than extinguishing its outputs.

Perhaps the most surprising player is the gut microbiome. Commensal bacteria wielding tryptophanases, aminotransferases and reductases convert dietary tryptophan into a diverse library of indoles, including indole-3-aldehyde, indole-3-lactic acid, indole-3-acetic acid and indole-3-propionic acid, many of which activate AHR in epithelial and immune cells. Landmark work by Zelante and colleagues showed in IDO1-deficient mice that microbiota-derived catabolites engage AHR and balance mucosal immunity through interleukin-22, and more recent studies demonstrate that lactic acid bacteria are particularly prolific producers of these ligands. Microbial compensation is not uniformly immunosuppressive: cooperative metabolism between Lactobacillus johnsonii and Clostridium sporogenes boosts indole-3-propionic acid, which promotes H3K27 acetylation at the Tcf7 super-enhancer and maintains progenitor exhausted CD8-positive T cells, thereby enhancing the efficacy of anti-PD-1 therapy across multiple cancer models. The microbiome, in other words, can either restore immune suppression or sharpen antitumor immunity, depending on which community members dominate.

The translational message of the review is a shift from enzyme-specific inhibition to network-based regulation. The authors draw a sharp distinction between target engagement, which merely confirms that IDO1 catalysis has been suppressed, and network suppression, which asks whether the broader biological output has actually fallen. Clinical data reinforce the point: in a phase 1/2 study of the irreversible inhibitor linrodostat combined with nivolumab, kynurenine fell across patient groups regardless of response, while therapeutic benefit associated instead with an interferon-gamma transcriptional signature and, in non-melanoma cohorts, with the combination of low TDO2 expression and high interferon-gamma signaling. Patient stratification in head and neck cancer likewise showed benefit only in subgroups with high baseline IDO1 RNA and context-specific immune signatures. The authors argue that future trials should pair serial plasma metabolomics with tissue-resolved assessment of IDO1, TDO2 and IL4I1 expression, AHR-responsive transcriptional markers and stool metagenomics, using adaptive designs that identify which compensatory node dominates in each patient. Emerging tools such as IDO1-targeting PROTACs, which degrade the protein and thereby disrupt both its catalytic and non-enzymatic signaling functions, may widen the mechanistic reach of treatment, but even protein removal cannot touch TDO2, IL4I1, microbial metabolism or downstream AHR activity. The lesson is sobering and clarifying at once: IDO1 is not a switch but one node in a dynamic, redundantly wired metabolic network, and effective immunometabolic therapy will require mapping exactly where compensation lives in each patient before deciding where to strike.

Subject of Research: Compensatory tryptophan metabolism and immune regulation pathways activated following IDO1 enzyme inhibition

Article Title: Compensatory pathways in tryptophan metabolism and immune regulation following IDO inhibition

Article References: Gontijo, I., Camurça, M., & Kfoury, J. R. (2026). Compensatory pathways in tryptophan metabolism and immune regulation following IDO inhibition. Molecular Biology Reports, 53(1), Article 1567. https://doi.org/10.1007/s11033-026-12707-9

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12707-9

Keywords: IDO1, tryptophan metabolism, kynurenine pathway, TDO2, IL4I1, aryl hydrocarbon receptor, immunotherapy resistance, epacadostat, gut microbiome, indole metabolites, serotonin pathway, immune regulation

Natural killer, or NK, cells are lymphocytes that can recognize and destroy abnormal cells without requiring the same antigen-specific priming used by conventional T cells. They release cytotoxic molecules, including perforin and granzymes, and produce signaling proteins that help coordinate broader antitumor immunity. Their activity is controlled by a balance of activating and inhibitory receptors, as well as signals from the surrounding tissue. In ovarian, breast, and prostate cancers, however, the tumor microenvironment can become metabolically hostile, nutrient-depleted, and rich in suppressive factors. Under these conditions, NK cells may accumulate inside tumors while progressively losing their ability to kill malignant cells. This state resembles exhaustion, but the researchers describe it more broadly as maladaptation because the cells are not simply inactive; they have been functionally reshaped by persistent environmental signals.

The study focused on AhR, a transcription factor that acts as a sensor for a wide range of chemical signals. AhR can be activated by compounds originating from pollutants, dietary components, drugs, and endogenous metabolism. Once activated, it moves into the cell nucleus and alters the expression of genes involved in immune development, metabolism, barrier function, and inflammatory responses. The researchers found that AhR activity has a context-dependent effect on NK cells. Brief or controlled activation can support NK-cell maturation and enhance antitumor functions. By contrast, prolonged stimulation appears to push the cells toward a dysfunctional state. The distinction is important because it shows that the same signaling system can be beneficial during an acute response but damaging when a tumor or chronic exposure keeps it switched on.

Using epithelial ovarian cancer as a model of an immunologically cold tumor, the investigators combined several experimental approaches to reconstruct this process. Their analyses included bulk gene-expression profiling, single-cell RNA sequencing, functional studies of isolated NK cells, mouse tumor models, clinical cohort data, and samples from patients with epithelial ovarian cancer. These methods allowed the team to examine both the molecular programs operating in individual immune cells and the clinical features associated with those programs. The single-cell analyses were particularly important because tumor-infiltrating NK cells are not a uniform population. Some retain cytotoxic activity, while others display gene-expression patterns associated with altered metabolism, persistent receptor signaling, and reduced effector function.

The proposed mechanism begins with GDF15, a stress-associated protein produced at elevated levels by chemoresistant tumor cells. GDF15 is known to participate in responses to cellular injury, metabolic imbalance, and inflammation, but in the tumor microenvironment it can also act as an immunomodulatory signal. According to the study, increased GDF15 is linked to enhanced IDO1 activity. IDO1 is an enzyme that converts tryptophan into kynurenine-pathway metabolites. This reaction can deprive local immune cells of tryptophan while generating molecules that influence immune-cell behavior. Kynurenine and related metabolites can enter NK cells and activate AhR, establishing a biochemical connection between tumor stress, altered amino-acid metabolism, and immune-cell reprogramming.

The resulting GDF15–IDO1–kynurenine–AhR axis appears to maintain NK cells in a state of chronic stimulation. At first, AhR signaling may help the cells adapt to the tumor environment and support their maturation. Over time, however, continual exposure to tumor-derived metabolites and stress signals changes the transcriptional and functional state of the cells. The NK cells become less effective at releasing cytotoxic molecules and killing cancer cells, even though they remain inside the tumor. This combination of retention and functional decline may be particularly advantageous to malignant tissue: immune cells are drawn into the tumor, but their capacity for surveillance and elimination is progressively weakened. The tumor can therefore appear immune-infiltrated without being genuinely immune-responsive.

The researchers also examined the possibility that environmental factors may reinforce this process. Because AhR responds to xenobiotics and other externally derived compounds, long-term exposure to AhR-activating chemicals could theoretically intensify signaling already initiated by tumor metabolism. The study places this possibility within a broader framework that links environmental toxicology to cancer immunology, including the potential influence of endocrine-disrupting compounds and dietary metabolites. The findings do not mean that any single environmental exposure directly causes ovarian cancer or NK-cell exhaustion. Rather, they raise the possibility that chronic exposure to chemical signals may interact with tumor-derived pathways and influence how immune cells behave after cancer has developed. This interaction could help explain why immune responses vary substantially among patients with apparently similar tumors.

A key experimental observation was that blocking AhR signaling restored aspects of NK-cell function. In the researchers’ models, inhibiting the pathway reduced the maladaptive program and improved the cells’ ability to respond against tumor targets. These results identify AhR as a possible therapeutic entry point, although the approach remains investigational. An AhR inhibitor would need to suppress harmful, persistent signaling without disrupting the receptor’s normal roles in immune development and tissue biology. The same caution applies to the upstream components of the pathway. GDF15 and IDO1 have functions in normal physiology, and broad inhibition could produce unintended effects. Future studies will need to determine which patients have pathway activity high enough to justify targeted treatment and whether blocking AhR can work safely alongside established immunotherapies.

The findings may also offer a strategy for predicting treatment response. The researchers propose that circulating GDF15 levels, combined with measurements of AhR activity in NK cells, could help identify patients whose immune systems are less likely to respond to checkpoint blockade. Such biomarkers would not replace clinical evaluation, but they could eventually help distinguish tumors that are merely infiltrated by dysfunctional immune cells from those with active antitumor immunity. The study further suggests that combining an AhR-targeting treatment with immune checkpoint inhibitors might help convert an immune-cold tumor into a more responsive one. For now, these implications require validation in larger patient groups and prospective clinical trials. Nevertheless, the work provides a mechanistic explanation for how chronic stress signals can transform a frontline immune defense into a source of persistent but ineffective tumor infiltration, and it places the GDF15–AhR pathway at the center of efforts to restore immune function in resistant cancers.

Subject of Research: Cells

Article Title: The Gdf15-xenobiotic receptor axis shapes NK cell maladaptation predicting cold tumors under environmental stress

News Publication Date: 5 June 2026

Web References: https://doi.org/10.1038/s41392-026-02690-9; https://www.pusan.ac.kr/eng/Main.do

References: Signal Transduction and Targeted Therapy, DOI: 10.1038/s41392-026-02690-9

Image Credits: Pusan National University

Keywords: Cancer immunotherapy, ovarian cancer, natural killer cells, cancer immunology, immune system, cold tumors, tumor microenvironment, immunotherapy, immune response, GDF15, IDO1, kynurenine, AhR, environmental stress, cancer research